GLP-1 Side Effects Week by Week: What to Expect

The general pattern

GLP-1 medications produce a predictable side-effect arc that follows the dose-escalation schedule. Most major obesity-indication trials use a similar protocol: start at a low dose (semaglutide 0.25 mg or tirzepatide 2.5 mg), escalate monthly by one dose increment, target a therapeutic dose between months 4 and 6. The side-effect profile tracks closely with this escalation.

Understanding the typical pattern helps in three ways: it sets realistic expectations for what you'll experience, it helps distinguish normal adaptation from problems that warrant clinical attention, and it informs decisions about whether to push through, slow down, or pause dose escalations.

The timeline below describes the typical experience for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). The exact patterns vary somewhat by molecule and individual physiology, but the broad structure is consistent across the class.

Week 1: Initial dose

The first injection at the starting dose (semaglutide 0.25 mg or tirzepatide 2.5 mg) usually produces the most acute initial side effects. Common experiences:

• Nausea — typically mild to moderate, often most prominent 24-72 hours after injection
• Fatigue or "off" feeling — frequently reported, sometimes attributed to the appetite-suppression itself
• Reduced hunger — often noticed even at the starting dose, particularly for tirzepatide
• Mild headache — common, usually resolves within 2-3 days
• Possible loose stools or constipation — direction varies by individual

What's normal: Mild to moderate nausea that's manageable with simple measures (eating slowly, smaller meals, avoiding rich/fatty foods, staying hydrated). Some fatigue. Reduced appetite.

What warrants attention: Severe vomiting (more than 2-3 episodes), severe dehydration, signs of acute pancreatitis (severe abdominal pain radiating to the back), or any allergic reaction.

Weeks 2-4: Adaptation phase at starting dose

For most patients, the second through fourth weeks at the starting dose see substantial improvement in early side effects:

• Nausea typically decreases — body adapts to the slowed gastric emptying
• Hunger reduction stabilizes — appetite suppression is more consistent
• Energy levels return to baseline for most
• GI patterns settle — most patients land on either mild constipation or mildly looser stools as a persistent pattern

This phase often produces the first noticeable weight loss. The combination of appetite suppression and slowed gastric emptying reduces caloric intake; weight begins to drift downward. Typical pattern: 1-3 pounds per week during early dose escalation.

Practical advice: Use this adaptation phase to develop sustainable eating patterns. The smaller portions you're naturally eating now should ideally translate into long-term habits, not just temporary medication-driven changes.

Week 4-5: First dose escalation

The first dose escalation (semaglutide 0.25 → 0.5 mg, or tirzepatide 2.5 → 5 mg) typically reactivates some side effects:

• Nausea often increases again for 2-7 days
• GI patterns may shift
• Hunger suppression deepens
• Weight loss often accelerates

This pattern — side effects flare with each dose escalation, then adapt — repeats throughout the titration period. Each escalation is typically less rough than the previous one because the body has acclimated to the underlying GLP-1 pharmacology.

Common mistake at this stage: Pushing through severe side effects to "get to" the target dose. The protocol allows extending time at a given dose if tolerability is poor. There is no clinical advantage to faster escalation; the eventual maintenance dose is what determines outcomes, not how quickly you reach it.

Weeks 6-12: Mid-titration phase

By weeks 6-12, most patients are at intermediate doses (semaglutide 1.0 mg, tirzepatide 7.5-10 mg) and have weathered the worst of the dose-escalation side effects.

• Nausea — typically mild and manageable for most
• Hunger suppression — substantial and increasingly automatic
• Weight loss — steady, typically 1-2 pounds per week
• Energy — most patients return to or exceed their baseline energy
• GI patterns — settled into individual norms (constipation more common than diarrhea)

Less common but worth noting at this stage:

• Hair shedding — typically temporary, related to rapid weight loss rather than the medication itself
• "Ozempic face" — facial fat loss may become noticeable; see our article on causes and prevention
• Reduced food interest beyond appetite — some patients report that food simply doesn't appeal the way it used to; this is the GLP-1 effect on reward circuits and is expected pharmacology
• Sulfur burps — occasional reflux-like sulfur-smelling belching; usually resolves with dietary adjustment

Months 3-6: Reaching the maintenance dose

By months 3-6, most patients have reached or are approaching their target maintenance dose. The pattern stabilizes:

• Side effects are typically minor for the majority who've made it through escalation
• Weight loss continues but begins to slow — the most rapid weight loss is usually in the first 4-6 months
• Eating patterns have adapted to the new appetite baseline
• Many patients report substantially less food noise/obsession (the cognitive aspect of appetite that GLP-1s appear to reduce)

This is also when several second-order considerations become more relevant:

Lean-mass loss becomes worth tracking. About 25-40% of weight lost on GLP-1 therapy is lean mass — this is similar to other weight-loss methods but starts to matter functionally over time. Resistance training and adequate protein intake (1.0-1.5 g/kg ideal body weight) substantially reduce the lean-mass-loss component.

Nutritional adequacy matters more as appetite stays suppressed. Reduced eating means smaller windows to get adequate protein, fiber, micronutrients, and hydration. A simple structure — protein-first at each meal, vegetables, modest carbohydrates, adequate water — sustains better outcomes than ad-libitum eating with very low intake.

Gallbladder considerations become relevant. Rapid weight loss increases gallstone risk independent of the medication; this is true for any weight-loss approach. Patients with prior gallbladder issues should discuss with their physician.

Months 6-12: Stabilization and plateau

Beyond 6 months, the pattern is typically stable:

• Side effects are minor for most
• Weight loss slows substantially — typically <1 pound per week, often a plateau pattern with intermittent further loss
• Appetite suppression continues but the relative novelty fades
• Long-term considerations (lean mass, nutritional adequacy, exercise habit) become the differentiators of outcomes

The plateau phase is normal and expected — the body adapts to the new lower body weight through reduced energy expenditure (metabolic adaptation) and partial restoration of hunger signaling around the new set point. Discussions of "plateau breaking" often involve dose increases, switching to a more potent molecule (semaglutide → tirzepatide → retatrutide when available), or adding amylin-pathway agents like cagrilintide (in the CagriSema combination).

Some patients experience a return of mild side effects when escalating doses to break a plateau — typically less intense than initial titration.

Beyond 12 months: long-term considerations

Long-term GLP-1 therapy carries considerations that aren't side effects per se but matter for sustained outcomes:

• Maintenance is indefinite for most patients. Stopping the medication typically results in weight regain over 6-18 months as appetite returns to baseline.
• Annual labs become important — typically lipid panel, HbA1c (even without diabetes), thyroid function, comprehensive metabolic panel.
• Bone density is a less-discussed concern. Rapid weight loss can affect bone mineral density; resistance training helps mitigate this.
• Mood — most patients report neutral or positive mood effects, but some report reduced motivation or "flat" affect. If this happens, discuss with your physician.

Red flags: when to call your physician

Most side effects are manageable and self-resolving. The following warrant prompt medical attention:

• Severe abdominal pain, especially radiating to the back — possible pancreatitis
• Severe vomiting that prevents adequate hydration
• Signs of gallbladder disease — pain in the upper right abdomen, particularly after meals
• Severe constipation with no bowel movement for 5+ days
• Allergic reactions — facial swelling, difficulty breathing, hives
• Vision changes — uncommon but documented; warrants evaluation
• Persistent severe fatigue beyond the initial adaptation phase
• Mood changes, particularly suicidal ideation — discuss promptly

Management strategies that actually help

What the trial data and clinical experience suggest works for managing side effects:

• Slow dose escalation. The protocol allows extending time at a given dose. There is no advantage to faster escalation if tolerability is poor.
• Eat slowly and stop earlier than you think. GLP-1s slow gastric emptying; finishing meals that felt normal pre-medication produces severe over-fullness and nausea.
• Hydrate aggressively. Most GLP-1 patients are mildly dehydrated; this worsens fatigue, constipation, and dizziness.
• Protein-first meals. Helps preserve lean mass and provides better satiety per calorie.
• Walk after meals. Supports digestion and helps with the post-meal fullness sensation.
• Avoid alcohol, high-fat meals, and large portions during titration. All amplify GI side effects.
• Antiemetic medications for severe nausea — talk to your prescriber. Ondansetron or similar can bridge the worst weeks.
• Magnesium and fiber for constipation. Often effective without prescription intervention.